Diagnexia, the UK’s leading provider of AI-powered digital pathology diagnostic services, is thrilled to announce an exclusive partnership with Artera to bring the ArteraAI Prostate Biopsy Assay to the UK. This collaboration represents a major step forward in bringing advanced personalised treatment plans to patients through the first multimodal AI risk stratification tool for those with localised prostate cancer.

A Unique Partnership Driving Innovation

Through this integration, Diagnexia and Artera deliver a unique proposition: a fast, accurate, and cost-effective solution to some of the greatest challenges in prostate cancer treatment personalisation.

Diagnexia’s position as a pioneer in digital pathology ensures that the ArteraAI Prostate Biopsy Assay is seamlessly integrated into clinical workflows, providing patients and clinicians with a tool for deciding on a personalised treatment plan with greater confidence. For Artera, this partnership allows the test to reach new markets and optimise patient outcomes on a broader scale.

The Future of Prostate Cancer Personalisation 

The ArteraAI Prostate Biopsy Assay is a powerful digital biomarker solution that combines patient clinical data—such as age, PSA levels, and T-stage—with AI interpretation of biopsy slides. This multimodal approach eliminates the need for additional invasive procedures or expensive molecular tests, providing clinicians with actionable insights. It is the first AI-enabled test of its kind to be recommended by the National Comprehensive Cancer Network® (NCCN®) in the USA for localised prostate cancer.

Key features include:

• Risk Assessment: Estimates the likelihood of distant metastasis and prostate cancer-specific mortality over 10 years.
• Therapy Guidance: Predicts the benefit of short-term androgen deprivation therapy (ADT) when combined with radiotherapy.
• Personalised Insights: Enhances decision-making for active surveillance and likelihood of future adverse pathology.

Why This Matters to Clinicians and Patients

The collaboration between Diagnexia and Artera addresses critical challenges in prostate cancer treatment planning that impact both clinicians and patients, including long wait times for test results, difficulty predicting disease progression, the high costs associated with molecular tests, and the frequent occurrence of inconclusive molecular test reports due to insufficient tissue quantity or quality. 

For patients, the ArteraAI Prostate Biopsy Assay offers a fast, non-invasive, and affordable risk stratification tool, with the added reassurance of expert secondary consultations from Diagnexia’s global network of pathologists.

For clinicians, this partnership provides access to a revolutionary AI tool that integrates seamlessly into existing workflows, offering data-backed insights to guide personalised treatment plans.

Leadership Insights

Donal O'Shea, CEO of Diagnexia:
“This partnership highlights the transformative potential of AI in revolutionising personalised cancer care. As the first and only global digital pathology service, Diagnexia has been at the forefront of digital innovation from the start. We see this new wave of digital biomarkers as a pivotal advancement, and by combining our expertise with Artera’s innovative technology, we aim to transform digital diagnostics services in the UK and beyond.”

Andre Esteva, CEO of Artera:
"We’re proud to join forces with Diagnexia to bring the ArteraAI Prostate Biopsy Assay to the UK. Together, we aim to empower clinicians with a state-of-the-art AI tool that optimises  patient outcomes and sets a new benchmark for prostate cancer care."

What This Partnership Means for Diagnexia

This collaboration strengthens Diagnexia’s position as a leader in cutting-edge pathology solutions and expands its portfolio to include advanced AI biomarkers. It also reinforces Diagnexia’s commitment to improving efficiency, quality, and patient outcomes while unlocking new revenue streams.

Availability

The ArteraAI Prostate Biopsy Assay, will soon be available for order through Diagnexia, providing clinicians in the UK with an advanced AI-powered diagnostic tool for prostate cancer risk stratification. For more information on how to order please visit here.

About Diagnexia

Diagnexia is a global leader in digital pathology, offering expert diagnostic services supported by advanced AI tools and a global network of subspecialty pathologists. With state-of-the-art facilities in Oxford and Exeter, Diagnexia is committed to transforming patient care through innovation and technology.

About Artera

Artera is a leading precision medicine company developing AI tests to personalise cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localised prostate cancer: ArteraAI Prostate Test.

Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomised trials.

Contact Information

Diagnexia Communications Team

Katie Higgins

Commercial Marketing Director

‍katie.higgins@deciphex.com

‍+35312210842

Artera Press Team

Lesley Swiger

lesley.swiger@antennagroup.com

‍(202) 869-1612